|
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
|
|
Scritto da Annals of Oncology - recent issues |
 Background
RET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in ALK- and ROS1-rearranged lung cancers, th ... ...
|
|
|
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
|
|
Scritto da Annals of Oncology - recent issues |
 Background
In the phase I KEYNOTE-001 study, pembrolizumab demonstrated durable antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). We sought to characterize the relationship between pembrolizumab dose, ... ...
|
|
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular C
|
|
Scritto da Annals of Oncology - recent issues |
 Background
The purpose of the protocol was to reduce the treatment burden in clinical stage I (CSI) seminoma by offering risk-adapted treatment. The protocol aimed to prospectively validate the proposed risk factors for relapse, str ... ...
|
|
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell
|
|
Scritto da Annals of Oncology - recent issues |
 Background
Emerging agents blocking the programmed cell death 1 (PD-1) pathway show activity in metastatic clear cell renal cell carcinoma (mRCC). The aim of this study was to evaluate the efficacy and safety of vascular endothelial ... ...
|
|
|
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
|
|
Scritto da Annals of Oncology - recent issues |
 Background
Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer. Preclinical studies show that anti-FGFR3 treatment slows down tumor growth, suggesting that this tyrosine kinase receptor is a candida ... ...
|
|
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes
|
|
Scritto da Annals of Oncology - recent issues |
 Background
Brentuximab vedotin (BV) is a key therapeutic agent for patients with relapsed/refractory classical Hodgkin lymphoma (cHL). The outcomes of patients experiencing disease progression after BV are poorly described. ... continua Aggiungi commento
|
|
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
|
|
Scritto da Annals of Oncology - recent issues |
 Background
Histologically, follicular lymphoma (FL) grades 1, 2 and 3A are composed of two distinct cell types, centroblasts and centrocytes. FL grade 3B is composed only of centroblasts and has been shown to differ in immunophenoty ... ...
|
|
|
Inizio Prec. 1 2 3 4 5 6 7 8 9 10 Succ. > Fine >>
|
| Pag 7 di 3690 |
